NewsMarketsIsraeli Company Floats On Canadian Market

Israeli Company Floats On Canadian Market

-

AFTER securing around $15m to boost its European operations IM Cannabis has become the first Israeli company to list its shares in Canada.

International Medical Cannabis (IMC) will trade under the ticker ‘IMCC’ on the Canadian Securities Exchange and may well be the first of many Israeli companies to follow this path.

Israeli daily financial website Calcalist recently reported on an anticipated flow of domestic companies to Canada.

With cannabis being legal in Canada it affords ambitious firms proximity to some of the leading global cannabis companies and access to an established cannabis-savvy financial system.

IMC has global ambitions with an keen focus on the European market and it will use the proceeds of a successful $15m private fund-raising round to bolster its footprint in Germany, Portugal and Greece

Oren Shuster, Chief Executive Officer, said it was doing ‘exceptionally well to position the company as a market leader in the EU’.

He said its European expansion strategy includes operations in Germany, a supply agreement in Europe, and will soon include operations in Portugal and Greece

IMC says it views the German market as particularly attractive given its size, regulatory structure and proximity to Israel, and earlier this year it purchased Adjupharm a German EU-GMP manufacturer and distributor. 

This business has licenses to import, export and distribute medical cannabis in Germany and has been distributing medical products to pharmacies for over 10 years, says IMC.

Peter
Peter
Peter McCusker is an experienced news and business editor, who believes it’s time to fully embrace the multiple, proven, medical benefits of the cannabis plant.

Latest news

Germany Seeing Sense, High Tide Strikes Deal With Major German Player, European Expansion For Bedrocan, Danish Buy-Out, Greek First, £2m UK Hemp Boost

THE German Government’s refreshingly honest approach to drugs and addiction is being demonstrated with a focus on the harms...

European Cannabis Stocks Review: Akanda Announces ‘First Significant Revenue Above Initial Projections’, Jazz Pharma Reimbursement Recommendation & Kanabo Climbs

Akanda  Akanda has enjoyed a sharp recovery in its share price this week, seeing its value return to levels not...

15% Of European Consumers Have Tried CBD, But Industry Held Back By ‘High Turnover Rate’ Of Users

THE European CBD market is set to see a ‘massive influx’ of previous and new consumers to the market...

Malta’s Pioneering Legal Cannabis Club Framework Announced, But Concerns Raised Licence Fees Could Push Many To Black Market

ON Friday (January 27) the Maltese Authority for the Responsible Use of Cannabis (ARUC) announced new guidelines set to...

Cannovum AG Establishes Cultivation Alliance For Germany

PRESS RELEASE CANNOVUM AG is currently founding the premier cultivation alliance for recreational cannabis in Germany. The aim of the...

Jazz Pharmaceuticals Receives NICE Recommendation For The Reimbursement Of Epidyolex (Cannabidiol) For The Treatment Of Seizures Associated With Tuberous Sclerosis Complex In England

PRESS RELEASE JAZZ Pharmaceuticals plc (Nasdaq: JAZZ) today announced that Epidyolex® (cannabidiol,100 mg/mL oral solution), developed by GW Pharmaceuticals ("GW"; now...

Must read

You might also likeRELATED
Recommended to you